MedTrace Logo

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16000

Last updated 2019-12-11

No results posted yet for this study

Summary

The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in routine clinical practice. The study has a retrospective design, and will be conducted in the US Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

15 mg, once daily

DRUG

Warfarin sodium

Individually adjusted dose

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-03-29
Completion
2019-03-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03359876 on ClinicalTrials.gov